keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab adherence

keyword
https://www.readbyqxmd.com/read/29557596/severe-asthma-in-pediatrics-outcomes-of-the-implementation-of-a-special-health-care-protocol
#1
Verónica Giubergia, María J Ramirez Farías, Verónica Pérez, Adriana González, Nancy Crespi, Nora Fridman, Claudio Castaños
INTRODUCTION: Severe asthma accounts for 5-7% of all asthma cases. The World Health Organization proposed a follow-up protocol to classify cases into severe, treatment-resistant asthma (STRA) or severe, difficult-to-control asthma (SDCA). OBJECTIVE: To analyze the clinical, functional, and therapeutic characteristics of patients with STRA or SDCA. METHODS: Cross-sectional, observational, and analytical study to assess the diagnosis, the extent of control (clinical and functional), comorbidities, treatment adherence, inhalation technique, and environmental factors in patients with severe asthma...
April 1, 2018: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/29518252/interventions-for-autumn-exacerbations-of-asthma-in-children
#2
REVIEW
Katharine C Pike, Melika Akhbari, Dylan Kneale, Katherine M Harris
BACKGROUND: Asthma exacerbations in school-aged children peak in autumn, shortly after children return to school following the summer holiday. This might reflect a combination of risk factors, including poor treatment adherence, increased allergen and viral exposure, and altered immune tolerance. Since this peak is predictable, interventions targeting modifiable risk factors might reduce exacerbation-associated morbidity and strain upon health resources. The peak occurs in September in the Northern Hemisphere and in February in the Southern Hemisphere...
March 8, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29466963/pediatric-severe-asthma-a-case-series-report-and-perspectives-on-anti-ige-treatment
#3
REVIEW
Virginia Mirra, Silvia Montella, Francesca Santamaria
BACKGROUND: The primary goal of asthma management is to achieve disease control for reducing the risk of future exacerbations and progressive loss of lung function. Asthma not responding to treatment may result in significant morbidity. In many children with uncontrolled symptoms, the diagnosis of asthma may be wrong or adherence to treatment may be poor. It is then crucial to distinguish these cases from the truly "severe therapy-resistant" asthmatics by a proper filtering process...
February 21, 2018: BMC Pediatrics
https://www.readbyqxmd.com/read/29017221/-biologicals-in-the-treatment-of-bronchial-asthma
#4
REVIEW
I Haasler, C Taube
Biologicals are a therapeutic option for patients with severe asthma. Difficult asthma in patients with untreated comorbidities or persistent trigger factors is much more common than severe refractory asthma. Optimized medical treatment, adherence to medication, elimination of trigger factors and treatment of comorbidities are essential before escalating the therapy with a biological. A careful phenotyping of patient with severe asthma is necessary because all available biological are only effective in certain phenotypes of the disease...
October 2017: Pneumologie
https://www.readbyqxmd.com/read/28958746/trends-in-omalizumab-utilization-for-asthma-evidence-of-suboptimal-patient-selection
#5
Molly M Jeffery, Nilay D Shah, Pinar Karaca-Mandic, Joseph S Ross, Matthew A Rank
BACKGROUND: Utilization trends of omalizumab, a first-in-its-class asthma biologic approved in 2003 for individuals not controlled by inhaled corticosteroids (ICSs), may reveal lessons in patient selection. OBJECTIVE: To describe utilization patterns for omalizumab since its introduction in 2003, with a focus on patient-level characteristics of patients for whom omalizumab was initiated. METHODS: Using a large US database of administrative claims, we identified privately insured and Medicare Advantage beneficiaries with asthma between 2003 and 2015...
September 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28062880/improving-asthma-outcomes-strategies-for-the-future
#6
EDITORIAL
Tow Keang Lim
No abstract text is available yet for this article.
December 2016: Annals of the Academy of Medicine, Singapore
https://www.readbyqxmd.com/read/27882879/treatment-of-chronic-spontaneous-urticaria-with-an-inadequate-response-to-h1-antihistamines-an-expert-opinion
#7
REVIEW
Christian Vestergaard, Elias Toubi, Marcus Maurer, Massimo Triggiani, Barbara Ballmer-Weber, Alexander Marsland, Marta Ferrer, André Knulst, Ana Giménez-Arnau
Chronic spontaneous urticaria (CSU) is characterized by the sudden, continuous or intermittent appearance of pruritic wheals (hives), angioedema, or both for six weeks or more, with no known specific trigger. The international EAACI/GA2 LEN/EDF/WAO urticaria guideline advises standard-dose, second-generation H1-antihistamines as first-line therapy. However, H1-antihistamine treatment leads to absence of symptoms in fewer than 50% of patients. Updosing of second-generation H1-antihistamines (up to fourfold) as recommended by the EAACI/GA2 LEN/EDF/WAO urticaria guideline as second-line therapy, can improve response, but many patients remain symptomatic...
February 1, 2017: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/27788886/evaluation-of-long-term-safety-and-efficacy-of-omalizumab-in-elderly-patients-with-uncontrolled-allergic-asthma
#8
Tugba Songul Tat, Aykut Cilli
BACKGROUND: Severe asthma management in elderly patients may be difficult because of increased comorbid conditions, polypharmacy, physiologic changes that occur with aging, incorrect use of inhaler devices, and poor adherence. OBJECTIVE: To evaluate the long-term safety and efficacy of the anti-IgE antibody omalizumab in elderly (aged ≥65 years) patients with uncontrolled allergic asthma. METHODS: The efficiency and adverse effects of omalizumab treatment were evaluated based on data extracted from medical records...
November 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27562427/drop-out-rate-among-patients-treated-with-omalizumab-for-severe-asthma-literature-review-and-real-life-experience
#9
REVIEW
M Caminati, G Senna, G Stefanizzi, R Bellamoli, S Longhi, F Chieco-Bianchi, G Guarnieri, S Tognella, M Olivieri, C Micheletto, G Festi, E Bertocco, M Mazza, A Rossi, A Vianello
BACKGROUND: In patients with asthma, particularly severe asthma, poor adherence to inhaled drugs negatively affects the achievement of disease control. A better adherence rate is expected in the case of injected drugs, such as omalizumab, as they are administered only in a hospital setting. However, adherence to omalizumab has never been systematically investigated. The aim of this study was to review the omalizumab drop-out rate in randomized controlled trials (RCTs) and real-life studies...
August 25, 2016: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/27071566/-therapy-goal-is-asthma-control
#10
Peter Stiefelhagen
No abstract text is available yet for this article.
April 14, 2016: MMW Fortschritte der Medizin
https://www.readbyqxmd.com/read/26346416/-severe-uncontrolled-asthma-in-patients-over-75%C3%A2-years-old-treatment-with-omalizumab
#11
P Romand, E Kelkel, C Saint-Raymond, N Glas, D Caillaud, G Devouassoux
INTRODUCTION: With an aging population and an increase in the prevalence of asthma, this disease is becoming more common in the elderly. Nevertheless, the management of severe asthma can be complex, due to an increased risk of uncontrolled disease in patients over 65 years old and partly to the inherent characteristics of old age: comorbidities, underestimation of the role of allergies, poor adherence, difficulties with inhalation devices, etc. CASE REPORTS: We report two cases of women over 75 with severe persistent allergic asthma not controlled by high doses of inhaled corticosteroids and long-acting beta-2-agonists in whom treatment with omalizumab was initiated...
May 2016: Revue des Maladies Respiratoires
https://www.readbyqxmd.com/read/26155196/prevalence-of-perennial-severe-allergic-asthma-in-italy-and-effectiveness-of-omalizumab-in-its-management-proxima-an-observational-2-phase-patient-reported-outcomes-study
#12
Giorgio Walter Canonica, Marta Bartezaghi, Raffaele Marino, Laura Rigoni
BACKGROUND: We designed the PROXIMA study (Patient-Reported Outcomes and Xolair(®) In the Management of Asthma) to determine the proportion of patients with severe asthma sensitive to perennial allergens, and to evaluate asthma control and treatment adherence up to 12 months in patients treated with omalizumab in Italian population. In addition, an ancillary study was designed to explore protein biomarkers and characterize them in relation to severe allergic asthma and treatment effects by proteomic approach...
2015: Clinical and Molecular Allergy: CMA
https://www.readbyqxmd.com/read/26021894/omalizumab-adherence-in-an-observational-study-of-patients-with-moderate-to-severe-allergic-asthma
#13
MULTICENTER STUDY
Susan L Janson, Paul G Solari, Benjamin Trzaskoma, Hubert Chen, Tmirah Haselkorn, James L Zazzali
BACKGROUND: Adherence to omalizumab is not well characterized and its association with asthma control has not been well established. OBJECTIVE: To evaluate adherence in patients initiating omalizumab in the Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate to Severe Asthma (EXCELS) observational study. METHODS: Adherence was assessed over 5 years using the proportion of patients who missed any dose, rates of doses missed, and proportions of patients with good (<10% doses missed) or poor (≥30% doses missed) adherence...
June 2015: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/25585581/severe-asthma-definition-diagnosis-and-treatment
#14
REVIEW
Marek Lommatzsch, J Christian Virchow
BACKGROUND: A minority of patients with asthma have uncontrolled or partially controlled asthma despite intensive treatment. These patients present a special challenge because of the extensive diagnostic evaluation that they need, insufficient evidence regarding personalized treatments, and their high consumption of health-care resources. METHODS: The definition, diagnosis, and treatment of severe asthma are presented on the basis of a selective literature review and the authors' clinical experience...
December 12, 2014: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/25528738/omalizumab-therapy-for-asthma-patients-with-poor-adherence-to-inhaled-corticosteroid-therapy
#15
RANDOMIZED CONTROLLED TRIAL
Leslie Hendeles, Yasmeen R Khan, Jonathan J Shuster, Sarah E Chesrown, Mutasim Abu-Hasan
BACKGROUND: Omalizumab, an anti-IgE monoclonal antibody, is administered by injection once or twice monthly in offices and clinics. It offers a potential alternative intervention for patients with allergic asthma that is not well controlled because of recalcitrant poor adherence to inhaled corticosteroid therapy. OBJECTIVE: To assess the effect of omalizumab therapy by measuring airway responsiveness to adenosine, a marker of allergic airway inflammation, and resource use...
January 2015: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/25459581/pediatric-asthma-guidelines-based-care-omalizumab-and-other-potential-biologic-agents
#16
REVIEW
Michelle Fox Huffaker, Wanda Phipatanakul
Over the past several decades, the evidence supporting rational pediatric asthma management has grown considerably. As more is learned about the various phenotypes of asthma, the complexity of management will continue to grow. This article focuses on the evidence supporting the current guidelines-based pediatric asthma management and explores the future of asthma management with respect to phenotypic heterogeneity and biologics.
February 2015: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/25439360/allergic-bronchopulmonary-aspergillosis
#17
REVIEW
Paul A Greenberger, Robert K Bush, Jeffrey G Demain, Amber Luong, Raymond G Slavin, Alan P Knutsen
There remains a lack of agreement on diagnostic criteria and approaches to treatment of patients with allergic bronchopulmonary aspergillosis (ABPA). The results of a survey of American Academy of Allergy, Asthma, & Immunology members regarding these 2 issues are presented and compared for concordance with published recommendations. The literature was reviewed for pertinent reports, and an electronic survey was conducted of American Academy of Allergy, Asthma, & Immunology members and fellows regarding diagnostic criteria, numbers of patients evaluated for ABPA, and treatment approaches...
November 2014: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/24508951/omalizumab-management-beyond-clinical-trials-the-added-value-of-a-network-model
#18
MULTICENTER STUDY
Marco Caminati, Gianenrico Senna, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Claudio Micheletto, Carlo Pomari, Silvia Tognella, Francesca Savoia, Valentina Mirisola, Andrea Rossi
BACKGROUND: Omalizumab is effective and safe in severe allergic asthma. Few data are available about its impact on lung function and on asthma comorbidities, long-term follow-up of treated patients, adherence, non-responders profile, and optimal treatment duration. OBJECTIVE: We aimed at evaluating omalizumab-related clinical outcomes and unmet needs in a real-life setting. METHODS: We created a collaborative network (NEONet - North East Omalizumab Network) involving 9 Allergy and Respiratory referral centres for severe asthma placed in the North-East of Italy...
October 2014: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/23830306/position-document-ige-mediated-allergy-to-egg-protein
#19
REVIEW
A Martorell, E Alonso, J Boné, L Echeverría, M C López, F Martín, S Nevot, A M Plaza
Egg is the food that most often causes allergy in young Spanish children, with an incidence of 2.4-2.6% in the first 2 years of life. The prevalence of sensitisation and allergy to egg is greater in children with allergy to cow's milk and in those suffering atopic dermatitis. The protein component from egg white is the cause of the allergic response in child. The major allergens in egg white are ovomucoid and ovalbumin. Most of the allergic reactions affect the skin, followed by gastrointestinal and respiratory systems...
September 2013: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/23299231/novel-therapies-in-asthma-leukotriene-antagonists-biologic-agents-and-beyond
#20
REVIEW
Eric S Papierniak, David T Lowenthal, Eloise Harman
Asthma is one of the most common conditions seen in clinical practice and carries both a significant disease burden in terms of patient morbidity and a high economic burden in both direct and indirect costs. Despite this, it remains a comparatively poorly understood disease, with only modest advances in treatment over the past decade. Corticosteroids remain the cornerstone of therapy. Both patient compliance with medications and physician adherence to evidence-based guidelines are often poor, and a high percentage of patients continue to have inadequately controlled disease even with optimal therapy...
January 2013: American Journal of Therapeutics
keyword
keyword
162738
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"